LONDON, Jan 6 (Reuters) - U.S. drugmaker Johnson & Johnson said on Tuesday it had started clinical trials of itsexperimental Ebola vaccine, which uses a booster developed byDenmark's Bavarian Nordic.
The initiation of the Phase I tests, which had been expectedabout now, marks further progress in the race to develop a shotagainst a disease that has killed more than 8,000 people in WestAfrica since last year.
Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, arealready in clinical development.
(Reporting by Ben Hirschler, editing by Louise Heavens)